Research Analysts Set Expectations for MAZE Q3 Earnings

Maze Therapeutics, Inc. (NASDAQ:MAZE) – Equities researchers at HC Wainwright issued their Q3 2026 earnings per share estimates for Maze Therapeutics in a research report issued to clients and investors on Friday, November 7th. HC Wainwright analyst A. Ghosh forecasts that the company will earn ($0.74) per share for the quarter. HC Wainwright has a “Buy” rating and a $50.00 price target on the stock. HC Wainwright also issued estimates for Maze Therapeutics’ Q4 2026 earnings at ($0.77) EPS.

MAZE has been the topic of several other reports. JPMorgan Chase & Co. upped their target price on shares of Maze Therapeutics from $27.00 to $37.00 and gave the company an “overweight” rating in a research report on Monday, September 29th. BTIG Research raised their price objective on Maze Therapeutics from $30.00 to $37.00 and gave the company a “buy” rating in a research note on Friday, September 12th. Weiss Ratings reissued a “sell (d)” rating on shares of Maze Therapeutics in a research report on Wednesday, October 8th. Wall Street Zen upgraded Maze Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, August 16th. Finally, Guggenheim boosted their price objective on shares of Maze Therapeutics from $19.00 to $34.00 and gave the company a “buy” rating in a research report on Monday, September 15th. Two investment analysts have rated the stock with a Strong Buy rating, six have issued a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat, Maze Therapeutics currently has a consensus rating of “Buy” and an average target price of $37.00.

Maze Therapeutics Stock Up 5.8%

Maze Therapeutics stock opened at $32.26 on Monday. Maze Therapeutics has a 52-week low of $6.71 and a 52-week high of $34.29. The firm’s fifty day moving average is $26.51 and its 200 day moving average is $17.64. The company has a market cap of $1.55 billion and a price-to-earnings ratio of -1.54.

Maze Therapeutics (NASDAQ:MAZE) last released its quarterly earnings data on Thursday, November 6th. The company reported ($0.66) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.74) by $0.08.

Insiders Place Their Bets

In other news, Director Richard H. Scheller sold 20,744 shares of Maze Therapeutics stock in a transaction on Monday, September 15th. The stock was sold at an average price of $22.37, for a total transaction of $464,043.28. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in the stock. Ameritas Investment Partners Inc. boosted its position in Maze Therapeutics by 82.6% in the 3rd quarter. Ameritas Investment Partners Inc. now owns 1,632 shares of the company’s stock valued at $42,000 after buying an additional 738 shares during the period. Bank of America Corp DE boosted its holdings in shares of Maze Therapeutics by 33.6% in the second quarter. Bank of America Corp DE now owns 5,782 shares of the company’s stock valued at $71,000 after purchasing an additional 1,455 shares during the period. China Universal Asset Management Co. Ltd. bought a new position in Maze Therapeutics in the third quarter worth approximately $52,000. CWM LLC purchased a new position in Maze Therapeutics during the 2nd quarter worth $28,000. Finally, New York State Common Retirement Fund bought a new stake in Maze Therapeutics during the 1st quarter valued at $25,000.

Maze Therapeutics Company Profile

We are a clinical-stage biopharmaceutical company harnessing the power of human genetics to develop novel, small molecule precision medicines for patients living with renal, cardiovascular and related metabolic diseases, including obesity. We are advancing a pipeline using our Compass platform, which allows us to identify and characterize genetic variants in disease and then link those variants to the biological pathways that drive disease in specific patient groups through a process we refer to as variant functionalization.